pSivida raises $15m for BioSilicon development
This article was originally published in Clinica
Executive Summary
Australian bio-nanotech firm pSivida has secured an additional $15m funding, following the sale of subordinated convertible debts to a New York-based institutional investor. The debts will mature three years from the date of closing, expected to be in mid-November, and are convertible into American Depository Receipts at an initial conversion price of $7.10. Perth-based pSivida says it will use the proceeds from the note sale for the expanded development of its proprietary product, BioSilicon. The company recently acquired Control Delivery Systems (CDS), a Boston, Massachusetts-based ophthalmic drug delivery company, and is planning to incorporate BioSilicon with CDS' Aeon technology.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.